Market Introduction
Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system. Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. It is a potentially debilitating disease, causing disruption in communication and coordination functions of the body.
Market Overview and Dynamics
The North America multiple sclerosis therapeutics market is expected to reach US$ 15,269.74 million by 2027 from US$ 9,144.98 million in 2019; it is estimated to grow at a CAGR of 6.8% from 2020 to 2027. The growth of the market is attributed to a few key driving factors such as the increasing prevalence of multiple sclerosis and rising funding for multiple sclerosis research. However, the high cost of the multiple sclerosis treatment hinders the market growth.
As per the National Multiple Sclerosis Society’s study in 2017, about 1 million adults (up to 913,925) were suffering from MS in the US. Therefore, the growing prevalence of multiple sclerosis is driving the growth of the North America multiple sclerosis therapeutics market. Due to rise in funding, extensive research is being carried on developing novel medicines and treatments for multiple sclerosis and other ways of identifying potential causes for multiple sclerosis. Various organizations such as National Institute of Neurological Disorders and Stroke, National MS Society, and Parkinson’s Action Network are undertaking extensive efforts to create novel therapies for MS, which is driving the growth of the market.
North America is recording the growing number of COVID-19 cases. Patients suffering from chronic health conditions, such as neurological diseases, are reporting delays in treatment. Several companies are cutting their clinical trial activities and delaying product launches in response to the COVID-19 pandemic. However, amid pandemic, many companies and research institutes in the US are taking an initiative to study the neurological manifestations of COVID-19. To accelerate research into the diagnosis, prevention, and treatment of the neurological complications due to COVID-19, several initiatives have been initiated. These factors are positively influencing the North America multiple sclerosis therapeutics market to a extent.
Key Market Segments
The North America multiple sclerosis therapeutics market, by drug class, is bifurcated into immunosuppressant and immunomodulators. The immunomodulators segment held a larger share of the market in 2019, whereas the immunosuppressants segment is anticipated to register a higher CAGR in the market during the forecast period.
By route of administration, the North America multiple sclerosis therapeutics market is bifurcated into injectable and oral. The injectable segment held a larger share of the market in 2019, and the same segment is anticipated to register a higher CAGR in the market during the forecast period.
Based on distribution channel, the North America multiple sclerosis therapeutics market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment held the largest share of the market in 2019, whereas the e-commerce segment is estimated to register the highest CAGR in the market during the forecast period.
Major Sources and Companies Listed
Some of the primary and secondary sources associated with this report on the North America multiple sclerosis therapeutics market are the Ministry of Health and Prevention (MoHAP), U.S Centers for Disease Control and Prevention (CDC), National MS Society and Multiple Sclerosis Association of America (MSAA).
Reasons to buy the report
- Determine prospective investment areas based on a detailed trend analysis of North America multiple sclerosis therapeutics market over the next years.
- Gain an in-depth understanding of the underlying factors driving demand for different addictions therapeutics segments in the top spending countries and identify the opportunities offered by each of them.
- Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
- Identify the major channels driving the North America multiple sclerosis therapeutics market, providing a clear picture of future opportunities that will help Analyze, resulting in revenue expansion.
- Channelize resources by focusing on the ongoing programs undertaken by the different countries within the North America multiple sclerosis therapeutics market.
NORTH AMERICA MULTIPLE SCLEROSIS THERAPEUTICS MARKET SEGMENTATION
By Drug Class
- Immunosuppressant
- Immunomodulators
By Route of Administration
- Injectable
- Oral
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
By Country
- US
- Canada
- Mexico
Company Profiles
- Merck & Co., Inc.
- Novartis AG
- Bayer AG
- Sanofi
- Bristol-Myers Squibb Company
- Horizon Therapeutics plc
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Takeda Pharmaceutical Company Limited
- F. HOFFMANN-LA ROCHE LTD
- Biogen
North America Multiple Sclerosis Therapeutics Market Strategic Insights
North America Multiple Sclerosis TherapeuticsMarket Report Highlights
| Report Attribute | Details |
| Market size in 2019 | US$ 9,144.98 Million |
| Market Size by 2027 | US$ 15,269.74 Million |
| CAGR (2020 - 2027) | 6.8% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By Drug Class
|
|
Regions and Countries Covered
|
|
| North America | US, Canada, Mexico |
| Market leaders and key company profiles |
|
North America Multiple Sclerosis Therapeutics Market Country and Regional Insights
